XML 29 R19.htm IDEA: XBRL DOCUMENT v3.20.2
License and Collaboration Agreements (Tables)
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License, Collaboration and Other Revenue
In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):
Three months ended September 30,Nine months ended September 30,
Partner
Drug or Drug Candidate
2020201920202019
Bristol-Myers Squibb Company
Bempegaldesleukin$— $— $50,000 $— 
Eli Lilly and Company
NKTR-358
— 1,500 1,259 5,200 
Amgen, Inc.
Neulasta®
1,250 1,250 3,750 3,750 
Other381 371 412 910 
License, collaboration and other revenue
$1,631 $3,121 $55,421 $9,860 
Changes in Deferred Revenue Balance from Collaboration Agreements
The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September 30, 2020 (in thousands):
Nine Months Ended September 30, 2020
Deferred revenue—December 31, 2019$8,071 
Recognition of previously unearned revenue(5,070)
Deferred revenue—September 30, 2020$3,001